REDEMPLO Launches in Germany, First EU Market for Arrowhead's FCS Drug
ARWR has more than doubled off its 52-week low of $18.725.
Summary
Arrowhead's REDEMPLO (plozasiran) is now commercially available in Germany, the first EU market, following its June 2026 European Commission approval. The drug is listed in the Lauer-Taxe database, enabling prescription, dispensing, and reimbursement. This launch marks the start of the company's European commercialization strategy for its first approved product. REDEMPLO's label allows use based on clinical diagnosis without genetic testing, a competitive advantage over existing FCS treatments. The company plans to expand to other European countries in the coming months. This follows the Q3 report showing REDEMPLO sales doubled, indicating growing commercial traction.
At the time of this announcement, ARWR was trading at $86.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.2B. The 52-week trading range was $18.73 to $95.49. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.